Seres Therapeutics (NASDAQ:MCRB - Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Wednesday, May 7th. Analysts expect Seres Therapeutics to post earnings of ($0.03) per share and revenue of $10.00 million for the quarter.
Seres Therapeutics Trading Down 1.4 %
Shares of Seres Therapeutics stock traded down $0.14 on Monday, hitting $9.49. 22,307 shares of the company traded hands, compared to its average volume of 155,264. Seres Therapeutics has a 52 week low of $7.18 and a 52 week high of $30.60. The stock's 50 day moving average price is $12.33 and its 200-day moving average price is $14.93. The company has a market cap of $82.77 million, a PE ratio of -41.23 and a beta of 2.89.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on the stock. Chardan Capital restated a "buy" rating and set a $25.00 price objective on shares of Seres Therapeutics in a report on Thursday, March 20th. The Goldman Sachs Group lowered their price objective on Seres Therapeutics from $20.00 to $15.00 and set a "sell" rating on the stock in a research report on Friday, March 14th. Finally, StockNews.com cut Seres Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $80.00.
Get Our Latest Stock Analysis on MCRB
Seres Therapeutics Company Profile
(
Get Free Report)
Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
See Also
Before you consider Seres Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seres Therapeutics wasn't on the list.
While Seres Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
